Dr. Feng Y. Jiang

Hematology Oncology | Hematology | Oncology
5640 N Adrian Hwy, 
Adrian, MI 
Accepting New Patients
Offers Telehealth
23 Years of Experience
5640 N Adrian Hwy, 
Adrian, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Feng Jiang is a Hematologist Oncology specialist and a Hematologist in Adrian, Michigan. Dr. Jiang has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Childhood Iron Deficiency Anemia. Dr. Jiang is currently accepting new patients.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Promedica Charles And Virginia Hickman Hospital
Promedica Toledo Hospital
Promedica Monroe Regional Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

PROMEDICA MULTI SPECIALTY PHYSICIANS
5640 N Adrian Hwy, Adrian, MI 49221
Other Locations
PROMEDICA MULTI SPECIALTY PHYSICIANS
2142 N Cove Blvd, Toledo, OH 43606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 4 Less Clinical Trials

20 Total Publications

Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Journal: Neuro-oncology practice
Published: March 20, 2025
Similar Doctors
Advanced in BRCA Positive Breast Cancer
Dr. Erin F. Cobain
Oncology | Hematology
Advanced in BRCA Positive Breast Cancer
Dr. Erin F. Cobain
Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (26.2 miles away)
734-936-5738
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Cobain is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Cobain has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Cobain is currently accepting new patients.

Sofia D. Merajver
Advanced in BRCA Positive Breast Cancer
Dr. Sofia D. Merajver
Oncology
Advanced in BRCA Positive Breast Cancer
Dr. Sofia D. Merajver
Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (26.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sofia Merajver is an Oncologist in Ann Arbor, Michigan. Dr. Merajver is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Angiosarcoma. Dr. Merajver is currently accepting new patients.

Advanced in BRCA Positive Breast Cancer
Dr. Jeffrey B. Smerage
Oncology | Hematology | Public Health and Preventive Medicine
Advanced in BRCA Positive Breast Cancer
Dr. Jeffrey B. Smerage
Oncology | Hematology | Public Health and Preventive Medicine

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (26.2 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Smerage is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Smerage is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Smerage is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jiang's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile